Competitive intelligence on 
 small-molecule drugs and 
 the 90,000 global patents 
 covering them 

Start your free trial now

DrugPatentWatch Ultimate Plan Preview

Details for Generic Name: prednisolone acetate

« Back to Dashboard

Summary for Generic Name: prednisolone acetate

Tradenames:18
Patents:5
Applicants:12
NDAs:27
Drug Master File Entries: see list79
Suppliers: see list12
Therapeutic Class:Hormonal Agents, Stimulant/Replacement/Modifying (Adrenal)
Inflammatory Bowel Disease Agents
Ophthalmic Agents

Pharmacology for Ingredient: prednisolone acetate

Clinical Trials for: prednisolone acetate

A Comparison of Three Different Formulations of Prednisolone Acetate 1%
Status: Completed Condition: Glaucoma; Cataract

A Bioequivalence Study of Tobramycin and Prednisolone Acetate Compared to PredForte
Status: Completed Condition: Eye Infections; Postoperative Complications

Efficacy and Tolerability of Prednisolone Acetate 0.5% Cream Versus Betamethasone Valerate 0.1% Cream in Cortisosensitive Dermatosis
Status: Not yet recruiting Condition: Dermatitis, Atopic; Dermatitis, Contact; Dermatitis, Seborrheic; Psoriasis

Study of Difluprednate vs. Prednisolone Acetate on Visual Acuity, and Corneal Edema Following Cataract Surgery.
Status: Completed Condition: Cataracts; Corneal Edema; Retinal Structural Change, Deposit and Degeneration; Visual Acuity Reduced Transiently

Biomarkers of Prednisolone Treatment (P05888)
Status: Completed Condition: Insulin Resistance; Hyperglycemia; Glucose Intolerance

Prednisolone Priming Study in Patients With Chronic Hepatitis B
Status: Recruiting Condition: Chronic Hepatitis B

Preoperative Methylprednisolone in Endovascular Aortic Repair
Status: Completed Condition: Abdominal Aortic Aneurysms

The Efficacy of Three Months-prednisolone Therapy for Chronic Eosinophilic Pneumonia
Status: Completed Condition: Eosinophilic Pneumonia; Chronic Disease

A Study to Compare Ocular Safety and Tolerability of Eye Drops Containing Prednisolone Acetate in Patients With Intraocular Inflammation After Cataract Surgery
Status: Completed Condition: Cataract Surgery

Efficacy Study of Adrenocorticotropin Hormone to Treat Multiple Sclerosis (MS) Relapses After Sub-responding to an Initial 3 Day Course of Intravenous (IV) Methylprednisolone
Status: Terminated Condition: Multiple Sclerosis

Courtesy of ClinicalTrials.org
See more clinical trials for this drug
Glossary
Applicant Tradename Generic Name Dosage NDA Approval Date Type RLD Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Schering
METIMYD
prednisolone acetate; sulfacetamide sodium
SUSPENSION/DROPS;OPHTHALMIC010210Approved Prior to Jan 1, 1982DISCNNo<disabled><disabled>
Allergan
PRED MILD
prednisolone acetate
SUSPENSION/DROPS;OPHTHALMIC017100Approved Prior to Jan 1, 1982RXYes<disabled><disabled>
Taro
FLO-PRED
prednisolone acetate
SUSPENSION;ORAL022067Jan 17, 2008DISCNNo5,881,926<disabled>Y<disabled>
Bel Mar
PREDNISOLONE ACETATE
prednisolone acetate
INJECTABLE;INJECTION083738Approved Prior to Jan 1, 1982DISCNNo<disabled><disabled>
Watson Labs
PREDNISOLONE ACETATE
prednisolone acetate
INJECTABLE;INJECTION083764Approved Prior to Jan 1, 1982DISCNNo<disabled><disabled>
This preview shows a limited data set
Subscribe for full access, or try a free trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

DrugPatentWatch Archives

You are viewing the current data set
Select a link below to view the archives:

 2000   2001   2002   2003   2004   2005   2006   2007   2008   2009   2010   2011   2012   2013   2014  

For more information try a free trial or see the plan comparison

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.

Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided information. There is no warranty that the information contained herein is error free. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2015 thinkBiotech LLC
ISSN: 2162-2639

Preferred citation:

Friedman, Y. Location of pharmaceutical innovation: 2000–2009 Nature Reviews Drug Discovery 9, 835–836 (2010).

Connect with Social Media:

Follow DrugPatentWatch on Twitter
Connect with DrugPatentWatch on Linkedin
Drug Patents on LinkedIn
`abc